Drug Information

Drug General Information
Drug ID
D0WK6V
Former ID
DNCL002911
Drug Name
PF-05231023
Drug Type
Antibody
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [524400]
Company
Pfizer
Target and Pathway
Target(s) FGF-21 ligand Target Info [533190]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Regulation of actin cytoskeleton
Pathways in cancer
Melanoma
Reactome Facilitative Na+-independent glucose transporters
Glucose transport
WikiPathways Regulation of Actin Cytoskeleton
Aryl Hydrocarbon Receptor
SREBP signalling
References
Ref 524400ClinicalTrials.gov (NCT01923389) Multiple Dose Study Of PF-05231023 In Obese Adult Subjects. U.S. National Institutes of Health.
Ref 533190Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab Dispos. 2015 Jun;43(6):803-11.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.